Oncolytics Biotech Stock Revenue
| ONCY Stock | USD 0.95 0.07 7.95% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Oncolytics Biotech's long-term financial health and intrinsic value.
Oncolytics | Build AI portfolio with Oncolytics Stock |
Oncolytics Biotech Company Revenue Analysis
Oncolytics Biotech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Oncolytics Biotech reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Oncolytics Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncolytics Biotech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics of similar companies.Oncolytics Biotech is currently under evaluation in revenue category among its peers.
Oncolytics Fundamentals
| Return On Equity | -2.14 | ||||
| Return On Asset | -0.76 | ||||
| Current Valuation | 85.18 M | ||||
| Shares Outstanding | 96.6 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 1.52 % | ||||
| Number Of Shares Shorted | 2.43 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 20.36 X | ||||
| EBITDA | (34.88 M) | ||||
| Net Income | (31.71 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.06 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Short Ratio | 1.67 X | ||||
| Earnings Per Share | (0.29) X | ||||
| Target Price | 4.03 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 85.31 M | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Working Capital | 12.19 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
| Net Asset | 20.19 M |
About Oncolytics Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.